SCHEMBL1388097

SCHEMBL1388097

C1=C(c2cc3ccccc3o2)CCN(Cc2nc3ccccc3[nH]2)C1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 12/20 0.67
DRD2 P14416 5/20 0.52
DRD3 P35462 4/20 0.52
HPGD P15428 1/20 0.50
HTT P42858 2/20 0.49
CYP2C8 P10632 2/20 0.47
CYP2C9 P11712 2/20 0.47
KCNH2 Q12809 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CCNT1 O60563 1/20 0.46
CDK9 P50750 1/20 0.46
USP2 O75604 2/20 0.43
LMNA P02545 2/20 0.43
MAPK1 P28482 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1388197 0.81 DRD4 (1.00) DRD4DRD2DRD3HPGDHTT
SCHEMBL8324685 0.79 DRD4 (0.61) DRD4DRD2DRD3HTTHTR2B
SCHEMBL1388241 0.77 DRD4 (0.67) DRD4DRD2DRD3HPGDHTT
SCHEMBL1388235 0.71 DRD4 (0.56) DRD4DRD2DRD3CYP3A4CYP2D6
SCHEMBL1388041 0.71 DRD4 (0.69) DRD4DRD2DRD3HPGDHTT
SCHEMBL1388193 0.71 DRD4 (0.65) DRD4DRD2DRD3HPGDHTT
SCHEMBL5157052 0.71 HTT (0.84) DRD4DRD2HPGDHTTCYP3A4
SCHEMBL1388460 0.70 DRD4 (0.67) DRD4DRD2DRD3HPGDHTT
SCHEMBL8567826 0.70 CYP2C8 (0.40) DRD4HPGDHTTCYP2C8CYP2C9
SCHEMBL1388159 0.70 DRD4 (0.66) DRD4DRD2DRD3HPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1235572-A2 METHOD TO TREAT PAIN UTILIZING BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2002-09-04 EP claimed
US-6362196-B1 N-METHYLASPARATIC ACID ANTAGONIST MERCK & CO., INC. 2002-03-26 US claimed
WO-2001030330-A2 METHOD TO TREAT PAIN UTILIZING BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2001-05-03 WO claimed
EP-0689535-B1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME (GB) 1998-09-23 EP claimed
JP-H08508030-A 1996-08-27 JP claimed
EP-0689535-A1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1996-01-03 EP claimed
WO-1994021615-A1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-09-29 WO claimed
EP-1235572-A2 METHOD TO TREAT PAIN UTILIZING BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2002-09-04 EP disclosed
US-6362196-B1 N-METHYLASPARATIC ACID ANTAGONIST MERCK & CO., INC. 2002-03-26 US disclosed
WO-2001030330-A2 METHOD TO TREAT PAIN UTILIZING BENZIMIDAZOLE NMDA/NR2B ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2001-05-03 WO disclosed
EP-0689535-B1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME (GB) 1998-09-23 EP disclosed
US-5714498-A Benzimidazole derivatives MERCK, SHARP, & DOHME, LTD. (GB) 1998-02-03 US disclosed
EP-0689535-A1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1996-01-03 EP disclosed
WO-1994021615-A1 BENZIMIDAZOLE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1994-09-29 WO disclosed